April 2025 clinical trial highlights
In the April 2025 clinical trial highlights, we'll showcase just a few of the many trials open for enrollment and seeking volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with idiopathic pulmonary fibrosis (IPF)
Ifetroban in IPF
- Study ID: NCT05571059
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: Cumberland Pharmaceuticals
- Study Contact: Ingrid Anderson, PhD, CCRP (615.627.4121, ianderson@cumberlandpharma.com)
Seeking participants with idiopathic pulmonary fibrosis (IPF)
BI 1839100 in IPF for cough
- Study ID: NCT06360094
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: Boehringer Ingelheim
- Study Contact: 1.800.243.0127, clintriage.rdg@boehringer-ingelheim.com
Seeking participants with pulmonary fibrosis (PF) and interstitial lung disease (ILD)
PFF Community Registry
- Study ID: NCT05382572
- Intervention: Observational
- Sponsor: Pulmonary Fibrosis Foundation
- Study Contact: registry@pulmonaryfibrosis.org
"I know the power community has. And if we’re all able to come together and join this registry to offer our insights, that is where the real power lies. We need all of the voices to be able to answer the questions that we have." -Samantha Kagel, Caregiver |  |
Research updates
PFF Community Registry surpasses 2,500 enrollments
I am proud to share that more than 2,500 members of the PF and ILD community have joined the PFF Community Registry.
Your participation is driving real progress. Every data point, every shared experience, every story is helping to shape the future of pulmonary fibrosis research and treatment.
If you haven’t yet added your voice, we invite you to join us. With each new participant, we gain deeper insights and move one step closer to the breakthroughs that will change lives.
Learn more and register today – your involvement truly matters.
 | Thank you! Sincerely, Jessica Shore, PhD, RN Senior Vice President, Clinical Affairs and Quality |
Learn more about the role NIH funding plays in PF researchHear from the PFF’s Chief Medical Officer, Amy Hajari Case, about how NIH funding drives life-changing advances in PF treatment. |  |